TwinEdge Bioscience Announces Launch of Innovative Company Focused on Digital Avatars for Oncology Drug Development

Lausanne, Switzerland – March 19th, 2025 – TwinEdge Bioscience SA, a new cutting-edge biotechnology company, is pleased to announce its formation and incorporation, marking a significant step forward in the field of oncology drug development. TwinEdge Bioscience, based at the world-renowned Biopôle in Lausanne, Switzerland, has been founded by a complementary team of leading scientists and business veterans, committed to revolutionizing cancer research through the application of digital avatars.

The company's primary focus is the development of highly advanced digital avatars designed to simulate human tumours, enabling more accurate, efficient, and scalable drug development for oncology therapies. By leveraging state-of-the-art digital modelling, TwinEdge Bioscience is aiming to shorten the drug discovery timeline, reduce costs, and improve clinical trial outcomes, all with the goal of advancing cancer treatments more quickly and effectively.

"We believe the power of digital avatars can transform the way we approach oncology drug development," said **Mike Prosser**, CEO and co-founder of TwinEdge Bioscience. *"By creating populations of detailed, virtual representations of human biology, we can simulate how new drugs will perform in patients long before clinical trials begin. This will allow us to streamline the process, reduce the risk of failure, and ultimately bring life-saving treatments to market faster."*

TwinEdge Bioscience's approach combines expertise in artificial intelligence (AI), data science, and cutting-edge biological research to create highly accurate models that replicate individual patient profiles. These digital avatars can simulate the effects of new oncology drugs on human cells, providing researchers with unparalleled insight into drug behaviour and efficacy. The avatars also have the potential to bring large scale patient population data to translational decision points, offering novel and invaluable insight to this key step in drug development.

"We are excited to bring together a team that shares a common vision and complementary skills," added **Ioannis Xenarios**, Professor of Computational Biology at the CHUV/UNIL and co-founder of TwinEdge Bioscience. *"Our mission is clear: to accelerate the development of breakthrough cancer therapies by harnessing the power of digital avatars. This will be a game-changer for the industry."*

TwinEdge CBO and Co-founder **Kevin Buyens,** formerly head of Corporate Development and Strategy at Crown Bioscience, noted *"The founding team includes world-renowned scientists with extensive experience in oncology and computational biology, alongside accomplished business leaders with deep knowledge in translational Pharma Services commercialization and strategy. This unique blend of scientific innovation and business acumen positions TwinEdge Bioscience at the forefront of the digital health revolution in oncology."*

TwinEdge Bioscience is already in the early stages of collaborations with academic institutions and pharmaceutical companies to advance its platform and accelerate the deployment of digital avatars in the oncology drug development process. With this strong foundation, the company is poised for significant impact and rapid growth in the coming years.

About TwinEdge Bioscience
TwinEdge Bioscience is a biotechnology company dedicated to the development of digital avatars for oncology drug discovery and development. By combining cutting-edge computational biology, artificial intelligence, and personalized medicine, TwinEdge Bioscience is transforming how new cancer therapies are developed. The company's goal is to reduce the time and cost of oncology drug development, while increasing the accuracy and effectiveness of treatments for cancer patients worldwide.

For media inquiries, please contact:
Kevin Buyens
CBO
TwinEdge Bioscience
Email: press@twinedgebio.com
Phone: +32 497529905
Website: www.twinedgebio.com